Two Thirds of the Sleep Apnea Trial Were Men. Nobody Reported Their Testosterone.
In December 2024 the FDA approved tirzepatide for moderate to severe obstructive sleep apnea in adults with obesity, which made it the first drug ever approved for the condition. Everything before it was a machine, a mouthpiece or a surgeon. The approval rested on two trials called SURMOUNT-OSA, and the headline result was strong enough that it did not need help from anyone's marketing department: the number of times per hour that people stopped breathing fell by roughly half to two thirds, and around half of the treated group ended the year under the threshold that defines the disease. What almost nobody noticed is who was in those trials. Study 1 was 67.1 percent male with a mean age of 47.9. Study 2 was 72.3 percent male with a mean age of 51.7. Middle aged men, carrying obesity, with untreated or partially treated severe sleep apnea, is close to a textbook description of the population in which testosterone comes back low. Sleep apnea has a well documented effect on the hormone axis, and it operates overnight, which is when most of a man's testosterone is made. The trials did not report a testosterone endpoint. This article is educational background on published trial data and known physiology. It is not medical advice, a protocol or a recommendation.
What the Two Trials Actually Did
SURMOUNT-OSA was not one study. It was two parallel randomized, double blind, placebo controlled trials run under a master protocol, and the split between them is the interesting design choice. Study 1 enrolled 234 adults with moderate to severe obstructive sleep apnea and obesity who were not using positive airway pressure. Study 2 enrolled 235 who had already been on positive airway pressure for at least three months and intended to stay on it. Both ran 52 weeks. Both used tirzepatide at the maximum tolerated dose, meaning 10 or 15 milligrams weekly, against placebo. The primary endpoint was change in the apnea hypopnea index, which counts how many times per hour of sleep breathing either stops completely or drops enough to matter. Moderate to severe means fifteen or more of those events every hour, every hour, all night. Splitting the trial this way answered two different questions at once. Study 1 asked whether the drug works in someone who is not being treated. Study 2 asked whether it adds anything on top of a machine that is already holding the airway open, which is the harder question and the one a sleep physician would ask first.
The Breathing Endpoint at 52 Weeks
Change in the apnea hypopnea index, meaning the number of times per hour of sleep that breathing stops or goes shallow, in the two SURMOUNT-OSA trials. Study 1 enrolled adults not using positive airway pressure. Study 2 enrolled adults already on it and planning to stay on it. Everyone had moderate to severe sleep apnea and obesity at entry. The treatment difference against placebo was 20.0 events per hour in Study 1 and 23.8 in Study 2.
The Result Was Large and It Was Not Subtle
At 52 weeks, participants on tirzepatide in Study 1 dropped 25.3 events per hour against 5.3 on placebo. In Study 2 the figures were 29.3 against 5.5. The treatment differences were 20.0 and 23.8 events per hour. In percentage terms Study 1 came out at a 55 percent mean reduction from baseline against 5 percent for placebo. Effects of that size are rare in this field. Positive airway pressure works better than anything else available and it does so only when it is worn, and adherence has been the persistent problem for as long as the machines have existed. A drug that produces this scale of change in a once weekly injection is a genuinely different kind of option. Roughly 42 percent of treated participants in Study 1 and 50 percent in Study 2 ended the year in remission or with mild sleep apnea that no longer produced symptoms. That last number carried most of the press coverage. It deserves a caveat that the coverage mostly skipped, which is that it describes a threshold crossing rather than a cure, and threshold crossings move around with weight, alcohol, sleeping position and which night the sleep lab happened to record.
How Many Ended the Year Under the Threshold
Proportion of participants in the tirzepatide arms who reached remission or mild sleep apnea without symptoms after 52 weeks. This is the figure that got the most attention when the results were presented, and it is worth reading carefully. It describes the treated arms only. It uses a threshold definition rather than a cure, and where someone sits relative to a threshold can move with weight, alcohol, sleep position and the night the study happened to record.
The Mechanism Is Weight, Not the Airway
Tirzepatide does nothing directly to the airway. It has no action on the genioglossus or the other pharyngeal dilator muscles, it does not change the arousal threshold, and it does not affect the loop gain of the respiratory control system. It is a dual GIP and GLP-1 receptor agonist that reduces how much people eat. Body weight fell 17.7 percent in Study 1 and 19.6 percent in Study 2 against 1.6 and 2.3 percent on placebo. The airway improved because the tissue around it got smaller. Fat in the tongue, in the lateral pharyngeal walls and around the neck loads a soft tube that has to stay open while the muscles holding it are switched off during sleep. Visceral fat adds to the problem from below by reducing lung volume, which reduces the downward traction that helps splint the upper airway open. Take enough of that mass away and the tube collapses less often. This is worth stating plainly because it sets a limit. The effect belongs to the weight loss, and there is no reason to expect it to persist independently of the weight.
What the Same 52 Weeks Did to Body Weight
Mean percent change in body weight across the same four arms. This is the reason the breathing numbers moved. Tirzepatide is not an airway drug and has no direct action on the muscles that hold the throat open during sleep. It removes fat, including the fat around the neck and tongue and the visceral fat that pushes up against the diaphragm, and the airway stops collapsing as often as a consequence.
What Sleep Apnea Does to the Hormone Axis Overnight
Testosterone in men is not secreted evenly across the day. Most of it is produced during sleep, driven by pulses of luteinizing hormone from the pituitary, and the concentration rises through the night to peak in the early morning. That rise is tied to sleep architecture and specifically to the arrival of the first REM period. Obstructive sleep apnea disrupts both halves of the system. Each apnea ends in a brief arousal, and in severe disease that happens dozens of times an hour, which fragments sleep so badly that consolidated REM periods barely form. Separately, the repeated drops in blood oxygen appear to act on the pituitary directly. Studies of middle aged obese men with sleep apnea have documented lower mean luteinizing hormone concentrations, reduced luteinizing hormone pulse amplitude, less pulsatile testosterone secretion, and loss of the normal coupling between the testosterone rise and the first REM episode. Severity tracks with the effect: the apnea hypopnea index correlates negatively with serum testosterone, and both the oxygen desaturation index and the oxygen nadir relate to the decline. The picture that emerges is not gonadal failure. The testes are fine. The signal arriving from above is degraded, which is a different problem with different implications.
Who Was Actually in the Room
Percentage of enrolled participants who were men, against a fifty percent line. Mean age was 47.9 years in Study 1 and 51.7 in Study 2. Two thirds to nearly three quarters male, middle aged, carrying obesity and severe untreated sleep apnea, is a close description of the population in which low testosterone gets found. No testosterone endpoint appears in the published results.
Obesity Is Sitting on Both Ends of This
The confound is obvious once you look for it, and it is the reason this question is hard to settle. Obesity independently lowers total testosterone through aromatase activity in adipose tissue, which converts testosterone to estradiol and feeds back on the hypothalamus, and through reductions in sex hormone binding globulin that pull the total number down further. Obesity also causes most of the obstructive sleep apnea in middle aged men. So when a man with a body mass index of 38 and an apnea hypopnea index of 50 comes back with a testosterone of 240, there are at least three plausible contributors and no clean way to separate them from a single blood draw. This matters for how the SURMOUNT-OSA population should be read. Those participants had both exposures at once. Whatever their testosterone was doing at baseline, the trial intervention removed close to twenty percent of their body weight and roughly half their nightly breathing events over the same 52 weeks. Both of those changes push in the same direction on the hormone axis, which makes the missing measurement more frustrating rather than less.
Treating the Apnea Alone Has a Mixed Record
If disrupted sleep and nocturnal hypoxia were the whole story, then putting someone on positive airway pressure should raise their testosterone. The evidence for that is inconsistent. Meta-analyses of continuous positive airway pressure and testosterone have not produced a reliable effect, and the studies that do show improvement tend to be in newly diagnosed patients or in cohorts where weight also changed. A more recent signal comes from work in men with severe obesity, where severe sleep apnea was associated with functional hypogonadism and treatment improved testosterone in newly diagnosed cases. Set against that, a secondary analysis of the INTERAPNEA randomized trial found that an interdisciplinary weight loss and lifestyle intervention raised circulating testosterone compared with usual care in men with overweight or obesity and moderate to severe sleep apnea. Read together, these results suggest that the weight component carries more of the hormonal effect than the breathing component does, or at least that fixing the breathing while leaving the weight in place does less than people expect. That is exactly the arrangement SURMOUNT-OSA Study 2 created, and it is exactly where a testosterone measurement would have been most informative.
The Same Result as a Proportion of Where People Started
Mean reduction in the apnea hypopnea index in Study 1, expressed as a percentage of each group's own baseline rather than as an absolute count of events. Reading the endpoint this way matters because a drop of twenty five events per hour means something different to a man starting at thirty than to a man starting at eighty. The percentage view is also what makes the placebo arm legible: five percent is roughly the year to year noise you would expect from repeat sleep studies in the same person.
- Mean AHI reduction (%)
The Arrow Also Runs the Other Way
There is a reason clinicians pay attention to this pairing beyond curiosity. Testosterone therapy has a long standing warning attached to sleep apnea, on the basis that exogenous androgens may worsen it. The mechanistic case involves changes to upper airway dimensions and to the ventilatory control system, and the human evidence is genuinely limited: small studies, short durations, mostly at doses above replacement, with inconsistent findings. What survives from that literature is not a firm causal claim but a reasonable caution, which is that starting testosterone in a man with untreated moderate to severe obstructive sleep apnea is a scenario clinicians want to know about beforehand. The relevance to a men's health audience in 2026 is direct. Low testosterone and obesity and heavy snoring cluster in the same men, and the telehealth channel that dispenses testosterone often has no polysomnogram in the file and no realistic way to obtain one. A man who is tired, gaining weight, and losing morning erections has a set of symptoms that map onto low testosterone and onto untreated sleep apnea equally well.
What the Trial Did Report, and Why the Gap Matters
SURMOUNT-OSA was not thin on secondary endpoints. It reported sleep apnea specific hypoxic burden, with a treatment difference of 70.1 percent minutes per hour in Study 1, along with high sensitivity C reactive protein, systolic blood pressure, and patient reported sleep disturbance and sleep related impairment. A separate analysis published in 2025 covered the cardiometabolic secondary outcomes in more detail. This was a thorough trial program that measured a great deal. Testosterone was simply not on the list, and there is no scandal in that. Trials are designed around a primary question, endpoints cost money and add burden, and the sponsor's question was whether the drug reduces apneas. The gap is still worth naming, because the result is a large, well controlled, year long experiment that simultaneously removed twenty percent of body weight and half the nightly hypoxic events in a mostly male, mostly middle aged cohort, which is close to the ideal design for isolating what those two exposures do to the hormone axis, and the sample went home without anyone drawing that tube.
How to Think About This Without Overreaching
The defensible statements here are narrower than the interesting ones. It is established that tirzepatide reduced apnea severity substantially in two randomized trials and that it did so through weight loss. It is established that obstructive sleep apnea is associated with lower testosterone, lower luteinizing hormone pulse amplitude and disrupted nocturnal secretion in men, and that severity tracks with the size of that association. It is established that obesity independently lowers testosterone through a separate route. What is not established is that treating sleep apnea with a GLP-1 based drug raises testosterone, by how much, in whom, or whether any change would outlast the weight loss that produced it. Nobody has run that trial. Anyone selling you a confident answer is extrapolating across a gap that the published data does not cover. The practical version of this for a man reading it is unglamorous and has nothing to do with peptides. If you snore, wake unrefreshed, and have a testosterone result you are unhappy about, the sleep study is the test that has not been done, and it is the one most likely to change what the number means.
Frequently Asked Questions
Have more questions? Contact us or explore our full peptide intelligence platform.
Related Articles
Tribulus Is Sold as a Testosterone Booster. Eight of Ten Trials in Men Found No Change in Male Hormones, and the Erection Benefit It Does Show Arrives Without a Testosterone Rise.
Does tribulus raise testosterone? Eight of ten trials in men found no change. A 180-man trial did show better erections. What the research found, plus safety.
Three Beers a Night for Three Weeks Cut Testosterone by About 7 Percent. The Bigger Cost to Men Who Train Shows Up in the Muscle.
Does alcohol lower testosterone? In a diet-controlled trial, about 40 grams of alcohol a day for three weeks lowered testosterone in middle-aged men by 6.8 percent. Heavy drinking lowers it far more, and alcohol after training cut muscle protein synthesis by 24 to 37 percent. An educational review of the dose, the timing and what a month off actually changes.
16:8 Fasting Loses About the Same Weight as Counting Calories. The Early Window and the Muscle Question Are What Actually Differ.
In four randomized trials, an 8-hour eating window produced between 2.3 kg more and 0.8 kg less weight loss than its comparison diet. The 12-month NEJM trial found no significant edge over calorie restriction. An early 7 am to 3 pm window did better, and one trial in trained men saw testosterone fall. An educational review of the time-restricted eating evidence for men.